Riddhi Siddhi Gluco Biols (BSE 524480)₹680.35+2.31%Trading & Distributors
In the Jun 2026 quarter (consolidated), Riddhi Siddhi Gluco Biols reported sales of ₹89.67 Cr, down 41.9% from Jun 2025, and net profit of ₹3 Cr, down 62.5% year on year. For the year to Mar 2026, sales were ₹235 Cr and net profit −₹11.97 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 18.10 | 135 | 50.55 | 14.23 | 48.81 | 44.27 | 27.98 | 154 | 32.04 | 40.00 | 9.03 | 89.67 |
| Expenses | 14.37 | 133 | 53.56 | 14.43 | 42.35 | 44.94 | 31.38 | 154 | 30.47 | 45.45 | 17.05 | 92.24 |
| Operating Profit | 3.73 | 2.49 | −3.04 | −0.23 | 6.43 | −0.77 | −3.46 | −0.26 | 1.57 | −5.53 | −8.07 | −2.67 |
| OPM % | 20.6% | 1.8% | −6.0% | −1.5% | 13.2% | −1.7% | −12.3% | −0.2% | 4.9% | −13.7% | −88.9% | −3.0% |
| Other Income | 20.51 | 17.58 | 8.62 | 17.89 | 19.51 | −53.00 | 28.22 | 19.66 | 20.61 | 12.66 | −16.85 | 16.22 |
| Interest | 2.76 | 2.09 | 1.75 | 1.77 | 2.94 | 2.52 | 2.57 | 3.75 | 5.14 | 4.20 | 4.50 | 6.23 |
| Depreciation | 2.71 | 2.69 | 2.65 | 2.18 | 2.03 | 2.15 | 2.13 | 2.04 | 2.05 | 2.07 | 2.03 | 2.29 |
| Profit before tax | 18.70 | 15.25 | 1.17 | 13.67 | 20.91 | −58.31 | 20.00 | 13.59 | 14.92 | 0.83 | −31.42 | 5.00 |
| Tax % | 47.5% | 57.8% | −1,750.9% | −74.8% | 36.2% | −7.3% | 76.9% | 40.7% | 7.7% | 256.1% | 4.4% | 39.9% |
| Exceptional items | −1.99 | −2.99 | −6.99 | −1.99 | −1.99 | −72.94 | 1.99 | −1.99 | −1.99 | −1.99 | −27.95 | −0.99 |
| Net Profit | 9.78 | 6.41 | 21.39 | 23.80 | 13.30 | −53.87 | 4.61 | 8.01 | 13.71 | −1.27 | −32.65 | 3.00 |
| EPS (Rs) | 11.76 | 9.24 | 32.06 | 33.67 | 18.85 | −50.38 | 5.07 | 11.00 | 18.90 | −2.22 | −45.43 | 4.27 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 341 | 507 | 802 | 680 | 575 | 497 | 222 | 173 | 267 | 136 | 235 | 171 |
| Expenses | 354 | 553 | 812 | 594 | 528 | 509 | 198 | 172 | 263 | 133 | 247 | 185 |
| Operating Profit | −13.03 | −47.08 | −10.02 | 85.13 | 48.11 | −14.02 | 24.04 | 1.01 | 4.01 | 3.01 | −12.03 | −14.70 |
| OPM % | −3.9% | −9.0% | −1.3% | 13.1% | 8.1% | −2.7% | 11.1% | 0.4% | 1.5% | 1.9% | −5.0% | −8.6% |
| Other Income | 134 | 111 | 76.21 | 62.17 | 50.19 | 59.18 | 14.05 | −51.17 | 67.23 | 12.04 | 36.13 | 32.64 |
| Interest | 33.04 | 50.07 | 62.03 | 40.06 | 31.05 | 26.02 | 8.01 | 8.01 | 9.01 | 10.01 | 18.01 | 20.07 |
| Depreciation | 27.95 | 34.94 | 33.94 | 34.93 | 36.90 | 36.92 | 12.98 | 11.97 | 10.98 | 8.99 | 7.99 | 8.44 |
| Profit before tax | 59.10 | −21.04 | −30.02 | 73.11 | 30.05 | −18.03 | 18.01 | −70.10 | 51.06 | −4.01 | −2.01 | −10.67 |
| Tax % | 26.0% | 120.0% | −129.0% | 8.0% | 20.0% | 242.0% | 88.0% | 22.0% | 15.0% | 226.0% | 488.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | −5.99 | 0.00 | 0.99 | 0.00 | −118 | 0.00 | 1.99 | −32.95 | −32.92 |
| Net Profit | 43.83 | −44.83 | 8.96 | 66.79 | 23.92 | −61.77 | 1.99 | −84.77 | 43.85 | −11.95 | −11.97 | −17.21 |
| EPS (Rs) | 56.08 | −59.73 | 26.46 | 67.99 | 45.93 | −65.33 | 3.10 | −118.64 | 61.29 | −17.01 | −17.75 | −24.48 |
| Dividend payout % | 5.0% | −3.0% | 0.0% | 3.0% | 0.0% | 0.0% | 32.1% | −1.0% | 5.0% | −18.0% | −17.0% | — |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.99 | 6.99 | 6.98 | 6.99 | 6.99 | 6.99 | 6.98 | 6.98 | 6.98 | 6.98 | 6.98 |
| Reserves | 1,359 | 1,316 | 1,379 | 1,426 | 1,415 | 1,444 | 1,494 | 1,422 | 1,525 | 1,539 | 1,498 |
| Borrowings | 444 | 680 | 473 | 352 | 270 | 228 | 154 | 80.71 | 72.70 | 101 | 282 |
| Other Liabilities | 262 | 365 | 278 | 289 | 294 | 258 | 177 | 178 | 163 | 134 | 98.52 |
| Total Liabilities | 2,072 | 2,369 | 2,138 | 2,073 | 1,987 | 1,938 | 1,833 | 1,688 | 1,768 | 1,780 | 1,886 |
| Fixed Assets | 783 | 769 | 743 | 722 | 748 | 770 | 737 | 392 | 383 | 434 | 426 |
| CWIP | 2.01 | 2.01 | 16.04 | 57.12 | 66.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 915 | 968 | 469 | 351 | 158 | 175 | 197 | 209 | 338 | 307 | 605 |
| Other Assets | 372 | 631 | 908 | 942 | 1,015 | 992 | 899 | 1,087 | 1,047 | 1,040 | 855 |
| Inventories | 32.13 | 372 | 369 | 445 | 207 | 219 | 56.17 | 5.02 | 5.02 | 45.21 | 44.15 |
| Trade receivables | 140 | 45.04 | 50.01 | 48.98 | 246 | 102 | 51.05 | 42.98 | 23.01 | 11.99 | 7.99 |
| Cash & equivalents | 2.99 | 4.99 | 1.99 | 4.99 | 31.94 | 2.99 | 0.00 | 10.99 | 0.00 | 0.00 | 109 |
| Total Assets | 2,072 | 2,369 | 2,138 | 2,073 | 1,987 | 1,938 | 1,833 | 1,688 | 1,768 | 1,780 | 1,886 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 0.00 | −285 | −34.10 | −1.01 | 116 | 130 | 161 | 1.01 | 9.02 | −28.06 | −9.02 |
| Cash from investing activity | 14.01 | 95.02 | 294 | 170 | 45.98 | −51.95 | −69.93 | 7.99 | 21.01 | 20.98 | −21.99 |
| Cash from financing activity | −54.97 | 192 | −263 | −169 | −131 | −108 | −93.97 | 1.99 | −40.98 | 7.99 | 140 |
| Net cash flow | −41.01 | 3.01 | −3.01 | 0.00 | 31.01 | −29.03 | −2.01 | 11.01 | −11.01 | 0.00 | 108 |
| Capex | 16.03 | 21.02 | 25.02 | 50.03 | 68.03 | 7.01 | 6.01 | 0.00 | 13.02 | 49.09 | 0.00 |
| Free cash flow | −14.01 | −305 | −58.02 | −50.99 | 50.02 | 137 | 160 | 1.01 | 2.01 | −73.07 | 11.01 |
| CFO / OP % | −14.0% | 600.0% | 174.0% | 9.0% | 294.0% | −979.1% | 746.0% | 2,300.0% | 621.0% | −705.0% | −46.0% |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 149 | 32 | 23 | 26 | 156 | 75 | 83 | 91 | 31 | 33 | 13 |
| Inventory days | 50 | 424 | 215 | 425 | 204 | 216 | 120 | 13 | 8 | 173 | 78 |
| Days payable | 179 | 131 | 44 | 75 | 75 | 80 | 115 | 26 | 12 | 29 | 25 |
| Cash conversion cycle | 21 | 326 | 195 | 377 | 286 | 212 | 88 | 78 | 27 | 178 | 66 |
| Working capital days | 12 | −34 | 216 | 292 | 379 | 222 | 626 | 1,110 | 636 | 1,153 | 523 |
| ROCE % | — | 1.0% | 2.0% | 6.0% | 3.0% | 0.0% | 4.0% | 3.0% | 5.0% | 5.0% | 3.0% |
For the Jun 2026 quarter, Riddhi Siddhi Gluco Biols reported sales of ₹89.67 Cr, down 41.9% year on year and net profit of ₹3 Cr, down 62.5% year on year. The operating margin was −3.0%.
Riddhi Siddhi Gluco Biols' sales for the year to Mar 2026 were ₹235 Cr; over the last twelve months they were ₹171 Cr.
Net profit for the year to Mar 2026 was −₹11.97 Cr, and −₹17.21 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−24.48.
Riddhi Siddhi Gluco Biols reported borrowings of ₹282 Cr at Mar 2026, against cash and equivalents of ₹109 Cr.
Cash from operations was −₹9.02 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹11.01 Cr.